modalities available. The modality used should be chosen based on the clinical questions to be addressed and on available resources. 7) The most popular clinical exercise tests in the order of increasing complexity are stair climbing, a 6-minute walk test (6-MWT), a shuttle-walk test, a cardiac stress test (e.g., Bruce protocol), and a cardiopulmonary exercise test. 8) A recent review of functional walking tests concluded that "the 6-MWT is easy to administer, better tolerated, and more reflective of activities of daily living than the other walk tests. 9) The 6-MWT is a practical and simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians are needed. 6, 7) It assesses the global and integrated responses of all the systems involved during the exercise, including the cardiovascular and pulmonary systems, systemic and peripheral circulation, blood, neuromuscular units, and muscle metabolism. 9) However, as a 6-MWT can be evaluated only in patients capable of independent walking, Kim et al. 6) conducted a motor function measurement using manual muscle testing method to overcome these limitations in patients incapable of independent walking.
The efficacy of ERT in patients with Pompe disease is affected by cross-reactive immunological material (CRIM) status and the presence of symptoms. CRIM-negative status has been recognized as a poor prognostic factor in Pompe disease. 10) CRIMnegative patients make no GAA protein and develop highly sustained antibody titers to ERT that render the treatment ineffective. 10) Antibody titers are generally low for the majority of CRIM-positive patients and there is typically a better clinical outcome. 10) Therefore, knowledge of CRIM status is important before ERT is administered. However, CRIM test ing is not available in Korea at present, and there is a difficult part of commissioning a sample for research within a short period of time to an overseas institution when performing a test. In a study conducted by Kim et al., 6) they measured neutralizing antibodies affecting the bioavailability of recombinant enzyme and found all 3 patients with infantile-onset Pompe disease had no alphaglucosidase IgG antibody, 2 patients with late-onset Pompe disease showed positive alpha-glucosidase IgG antibody level.
